PatternsRadar
Sign in

ORCHPHARMAOrchid Pharma Limited

NSE
960.40INR+11.80 (+1.24%)Close · 20 Nov 2026
14 Nov 2026Last results
HealthcareSector
Pharmaceuticals & BiotechnologyIndustry
₹5,751 CrMarket cap
127.7P/E (TTM)
50.5%Delivery

Filings & corporate actions

25 results filed
CSV
Next results · Q3 FY27
Expected 10 Feb 2027 – 13 Feb 2027
Estimate: filed 41–44 days after quarter end, last 5 times
2026
  • 14 NovresultsResults · Q2 FY27 · consolidated and standalone+4.5%NSE
  • 17 OctshareholdingShareholding · 30 Sept 2026-1.9%NSE
  • 3 OctshareholdingShareholding · 1 Aug 2026-2.4%NSE
  • 14 AugresultsResults · Q1 FY27 · consolidated and standalone-4.5%NSE
  • 14 AugresultsResults · Q4 FY26 · consolidated and standalone-4.5%NSE
  • 21 JulshareholdingShareholding · 30 Jun 2026-2.3%NSE
  • 25 MayresultsResults · Q4 FY26 · consolidated and standalone+1.3%NSE
  • 20 AprshareholdingShareholding · 31 Mar 2026-4.2%NSE
  • 11 FebresultsResults · Q3 FY26 · consolidated and standalone-2.6%NSE
  • 21 JanshareholdingShareholding · 31 Dec 2025-0.7%NSE

Reaction to results · all yearsrose on day 0 in 11 of 25 CSV

QuarterFiledDay 0+5D+20DRel vol
Q2 FY2714 Nov 2026+4.5%——11.5×
Q1 FY2714 Aug 2026-4.5%-0.7%-5.5%2.8×
Q4 FY2625 May 2026+1.3%+17.0%+38.9%1.5×
Q3 FY2611 Feb 2026-2.6%-2.9%-25.8%4.2×
Q2 FY2611 Nov 2025-1.3%+3.5%+1.4%5.1×
Q1 FY2612 Aug 2025+1.2%+3.5%-6.4%1.3×
Q4 FY2528 May 2025-5.0%+2.8%-0.1%4.1×
Q3 FY2513 Feb 2025-15.2%-29.1%-34.7%10.5×
Q2 FY2512 Nov 2024+2.0%+1.7%+17.0%1.8×
Q1 FY2513 Aug 2024-1.5%-2.2%+7.5%0.5×
Q4 FY2424 May 2024-0.2%-2.9%+16.3%1.3×
Q3 FY2410 Feb 2024+3.1%+9.1%+2.4%2.5×
Q2 FY245 Nov 2023+1.9%+10.2%+17.5%1.7×
Q1 FY2411 Aug 2023-4.9%-6.6%-8.6%1.0×
Q4 FY2311 May 2023+4.9%+2.2%+0.5%4.0×
Q3 FY2310 Feb 2023+3.5%+9.5%+4.5%3.6×
Q2 FY2315 Nov 20220.0%-4.1%-9.2%0.7×
Q1 FY2310 Aug 2022-1.0%-1.5%+6.8%1.0×
Q4 FY2213 May 2022+0.4%-4.3%-6.5%0.3×
Q3 FY2213 Feb 2022-2.1%-9.3%-8.9%1.7×
Q2 FY2215 Nov 2021-1.0%-6.0%-5.4%0.5×
Q1 FY2214 Aug 2021-4.7%-10.0%-2.2%0.4×
Q4 FY2123 May 2021-0.3%-3.8%-6.4%0.7×
Q3 FY2110 Feb 2021+5.0%+34.0%+178.4%4.2×
Q2 FY2112 Nov 2020+5.0%+39.9%+188.6%—
Average-0.5%+2.1%+15.0%

Close-to-close from the session before the filing could trade. Day 0 is the first session after it.

Growth · Q2 FY27

Revenue YoY+76.3%
Profit YoY—
Interest cost YoY-25.1%
Revenue QoQ+12.2%
Profit QoQ+786.8%
CAGR2Y3Y4Y5Y6Y7Y
Revenue+16.2%+17.6%+17.7%+22.5%——
Profit-38.5%-22.3%————

Key data

Open948.60
Day range943.85 – 970.15
52-week range480.00 – 1,143.50
From 52w high-16.0%
RSI (14)59.4
ATR (14)44.35
Volume66.8K
Avg volume (20D)1.10L
Rel volume0.61×
Volatility (1Y)44.6%
Turnover₹6.4Cr
Traded value (NSE)₹6.4Cr
VWAP961.11
SMA 50 / 200945.30 / 825.53
Price band20%

Delivery percentage

Latest · 20 Nov 202650.5%
20-day avg43.3%
1-year avg47.8%
Percentile (own history)23rd
Range9.7–100.0%
Sessions1,495

Over the last 20 sessions ORCHPHARMA settled 43.3% of its traded quantity, which is ordinary for an NSE equity. Its one-year average is 47.8%, so recent sessions are running 4.5 points lower than usual. The latest session ranks higher than 23% of the 1,495 sessions on record for it.

What delivery percentage measuresScan the whole market on delivery

Dividends, deals & holders

Dividend yield0.00%
Dividend, trailing 12M₹0.00
Paid every year for0 yr
Shareholders33.8K · +1.6% QoQ
Net bulk deals, 30D0.00%
Block deals, 30D₹0
Last bulk buy539 days ago

Performance returns

1D1W1M3M6M1Y
Price+1.24%+8.59%+9.69%-2.00%+35.74%+19.50%

Valuation

Market cap₹5,751 Cr
Market cap (NSE)₹5,751 Cr
Free-float cap₹1,469 Cr
P/E (TTM)127.7
P/E (NSE)126.1
EPS (TTM)7.52
P/B3.5
Net margin (TTM)3.7%
Other income / PBT78.1%
ROE3.1%
Debt / equity0.33
Shares outstanding5.99Cr
Listed2 Nov 2020

Ownership

Promoter74.45%
Promoter Δ QoQ0.00 pp
Public25.55%
FII0.93%
DII17.44%
Pledged0.00%

Quarterly results · consolidated

Q3 FY26Q4 FY26Q1 FY27Q2 FY27
Revenue (₹ Cr)207.3368.3304.2341.3
YoY chg-4.6%+55.1%+75.9%+76.3%
Net profit (₹ Cr)(12.6)25.83.228.6
YoY chg-160.7%+15.9%-78.4%—
Net margin-6.1%7.0%1.1%8.4%
EPS-2.494.310.544.77

Shareholding over time

By quarter

30 Sept 2026 · promoter 74.45% · public 25.55%
30 Sept 2021: promoter 90.00%31 Dec 2021: promoter 90.00%31 Mar 2022: promoter 90.00%30 Jun 2022: promoter 89.96%30 Sept 2022: promoter 89.96%31 Dec 2022: promoter 89.96%31 Mar 2023: promoter 89.96%27 Jun 2023: promoter 72.40%30 Jun 2023: promoter 72.40%30 Sept 2023: promoter 72.40%31 Dec 2023: promoter 69.84%31 Mar 2024: promoter 69.84%30 Jun 2024: promoter 69.84%30 Sept 2024: promoter 69.84%31 Dec 2024: promoter 69.84%31 Mar 2025: promoter 69.84%30 Jun 2025: promoter 69.84%30 Sept 2025: promoter 69.84%31 Dec 2025: promoter 69.84%31 Mar 2026: promoter 69.84%30 Jun 2026: promoter 69.84%1 Aug 2026: promoter 74.45%30 Sept 2026: promoter 74.45%
2021-092026-09
  • Promoter
  • Public and others
Promoter
74.45%
Public
25.55%
Promoter change
0.00 pp
Filed
17 Oct 2026
FII
0.93%
DII
17.44%
Promoter pledged
0.00%

Who the public is

Mutual funds
16.88%

-0.02 pp QoQ

Insurance
0.01%

0.00 pp QoQ

FPI
0.93%

+0.01 pp QoQ

Retail ≤ ₹2L
4.49%

+0.13 pp QoQ

HNI > ₹2L
0.76%

-0.01 pp QoQ

NRI
0.35%

0.00 pp QoQ

Bodies corporate
1.34%

+0.01 pp QoQ

Shareholders
33,790

+1.6% QoQ

Major holders

As of 30 Sept 2026
HolderTypeHolding
Triveni TrustPromoter · Other32.62%
MANISH DHANUKAPromoter · Individual10.94%
Pushpa Dhanuka TrustPromoter · Other9.68%
QUANT MUTUAL FUND - QUANT SMALL CAP FUNDMutual fund5.79%
MAMTA DHANUKAPromoter · Individual5.20%
ARJUN DHANUKAPromoter · Individual4.82%
KOTAK MAHINDRA TRUSTEE CO LTD AND 6 OTHERS WITH SAME PANMutual fund3.99%
UMA DHANUKAPromoter · Individual3.15%
PUSHPA DHANUKAPromoter · Individual3.09%
UTI VALUE FUND AND 3 OTHERS WITH SAME PANMutual fund3.09%

Every promoter-group member, and each public holder above 1%, as filed.

Promoter and public shares of total equity, from the pattern filed each quarter. Institutional, pledge and public-breakdown figures come from the filing's XBRL, which most filings before Sep-2021 lack, so they are absent there rather than zero. Changes are against the previous filing.

Insider trades

Insiders net, 30d
₹0
Insiders net, 90d
₹0
Promoters net, 90d
₹0
Insider buyers, 90d
0
Last promoter buy
none on record
Disclosures on record
4
0 open-market of the newest 4
By year

No open-market insider trades among the recent disclosures.

SEBI insider-trading disclosures, equity only. Dated by the day NSE broadcast them; the trade itself is often weeks earlier. The figures count promoters, directors and KMPs buying or selling on the exchange — not ESOPs, gifts, transfers within the promoter group or pledges. Stake is the holding after, as filed; the change beneath it scales that by the share counts before and after. Regulation is the PIT clause cited, and “told” the day the insider informed the company.

How the insider figures are countedPromoters buying in the open market, market-wideEvery stock on this session

Bulk & block deals · 30 May 2025

CSV
1 of 1 deals
By year
DateDealClientQuantityPriceValue
30 May 2025Buy · bulkUTI MUTUAL FUND3.67L615.37₹22.6Cr

A bulk deal is a client trading over 0.5% of the company’s shares in a day; a block deal is one large trade in the separate block window. Quantities and prices are as NSE published them, not split-adjusted.

Every stock on this session →

Takeover-code disclosures

Loading…

Filed under SEBI’s takeover regulations when a holding crosses 5% of the company, and again with every 2% it moves after that. Shares and percentages as filed.

Every stock on this session →

Short selling, lending & margin

Loading…

Shares sold short on the day, as brokers reported them to NSE at the close. As reported, not split-adjusted.

Exchange surveillance

20 Nov 2026
  • P/E > 50 (4 quarters) · since 12 Jan 2026 — P/E above 50 on the last four quarters’ earnings.

Price band: 20% · not in the F&O ban.

From NSE’s daily surveillance, price-band and position-limit files. A stock enters the F&O ban when open interest passes 95% of its market-wide position limit and leaves it below 80%; until then no new positions can be opened. CSV: measures · band changes.

Every stock on this session →

Financials · quarterly statement

₹ crore, as filed
By year
 Q3 FY24Q4 FY24AQ1 FY25Q2 FY25Q3 FY25Q4 FY25AQ1 FY26Q2 FY26Q3 FY26Q4 FY26ARQ1 FY27Q2 FY27
Revenue from operations220.6217.1244.4222.7217.3237.5172.9193.5207.3368.3304.2341.3
Other income7.613.47.67.58.53.911.410.85.67.81.817.8
Total income228.2230.5252.0230.2225.8241.4184.4204.3212.9376.1306.0359.0
Total expenses198.0200.1223.9204.3203.4222.3170.7207.6217.9351.0303.4332.2
└ Finance costs3.53.53.53.33.83.93.33.73.22.02.23.6
└ Depreciation9.38.48.48.68.68.98.78.99.010.910.911.4
Profit before tax30.230.428.125.922.519.113.7(3.3)(12.1)24.82.626.8
Tax expense0.0(3.1)(0.2)0.00.0(0.0)0.00.00.00.00.1(0.0)
Net profit29.433.029.427.220.822.314.9(5.7)(12.6)25.83.228.6
EPS6.186.815.795.374.104.402.94-1.13-2.494.310.544.77
Net margin13.34%15.18%12.01%12.23%9.56%9.39%8.62%-2.96%-6.09%7.02%1.06%8.38%
PBT margin13.69%13.99%11.51%11.63%10.33%8.04%7.93%-1.72%-5.86%6.75%0.87%7.86%
Tax rate0.00%-10.27%-0.55%0.00%0.00%-0.21%0.00%——0.01%2.73%-0.17%

A audited · R restated by a later filing · negatives in parentheses. EPS and the share count are restated onto the same split-adjusted basis as the price chart, so they can be read against it; every rupee figure is exactly as filed. The balance sheet and cash flow arrive only with the half-year and annual filings, and are in their own section below. Latest filed 14 Nov 2026.

Balance sheet & cash flow · half-yearly

₹ crore, as filed
By year

Balance sheet

 FY23H1 FY24FY24H1 FY25FY25H1 FY26FY26H1 FY27
Total assets1,225.21,492.11,553.91,635.11,687.91,722.02,258.42,652.4
Current assets501.0497.4790.8833.4807.4704.4929.3955.0
└ Cash & equivalents22.640.43.64.421.142.07.146.6
└ Other bank balances8.09.9263.0239.5158.5106.576.49.6
└ Current investments0.00.00.00.00.00.00.00.0
└ Trade receivables215.2187.6195.5215.2241.8202.2381.4348.2
└ Inventories228.7222.4264.2320.6326.4306.2372.3422.1
Total equity688.61,107.81,169.51,224.21,267.31,273.81,564.31,632.3
└ Attributable to owners688.61,107.81,169.51,224.21,267.31,273.81,564.31,632.3
└ Non-controlling interest———0.00.0—0.0—
└ Share capital40.850.750.750.750.750.759.959.9
Borrowings331.3146.5134.5164.4174.2281.2301.4543.7
└ Current182.59.914.038.542.647.2116.7204.6
└ Non-current148.8136.7120.4125.9131.6234.0184.7339.1
Trade payables181.8225.4229.6223.8222.1148.9346.7396.3
Current liabilities371.9239.0260.0281.1285.6210.2491.2652.3
Total liabilities536.6384.2384.4410.9420.6448.2694.11,020.1
Net debt300.796.2(132.1)(79.5)(5.4)132.7217.9487.4
Debt / equity0.480.130.110.130.140.220.190.33
Current ratio1.352.083.042.962.833.351.891.46

Cash flow, year to date

 FY23H1 FY24FY24H1 FY25FY25H1 FY26FY26H1 FY27
Operating cash flow18.696.2126.0(15.1)19.211.5125.6117.8
└ Capex(84.9)(23.4)(64.8)(40.9)(150.1)(158.8)(389.6)(395.4)
Free cash flow(66.3)72.861.2(56.0)(130.9)(147.2)(264.0)(277.7)
Investing cash flow(31.5)(276.1)(312.0)(7.2)(26.9)(90.6)(276.9)(314.6)
Financing cash flow31.2197.8167.023.125.2100.0137.1236.3
└ Dividends paid0.00.00.00.00.00.00.00.0
└ Buybacks0.00.00.00.00.00.00.00.0
Net change in cash18.317.8(19.0)0.817.520.9(14.1)39.5

From the half-year and annual results filings: the balance sheet from September 2022, the cash flow from September 2020. Those are when NSE’s XBRL began to carry each statement; earlier filings have it only in the attached PDF. Cash flow columns are year to date, so an H1 column covers April to September and an FY column the full year. Outflows are in parentheses. Net debt is borrowings less cash, bank balances and current investments; for banks, NBFCs and insurers it, debt to equity and the current ratio are left blank because their statements are not built that way.

Announcements & board meetings

Loading…

As the company filed them with NSE, newest first. Board meetings are dated by the meeting, which is usually a week or more after the intimation.

Every stock on this session →

ORCHPHARMA at a glance

  • ORCHPHARMA closed at ₹960.4 on 20 Nov 2026, +1.24% on the day, +19.5% over one year, 16.0% below its 52-week high of ₹1,143.5.
  • Delivery was 50.5% of traded quantity on 20 Nov 2026, the 23rd percentile of its own 1,495 sessions with a reading (20-session average 43.3%, 1-year average 47.8%).
  • Market capitalisation is ₹5,751 crore at a trailing P/E of 127.7 (trailing EPS ₹7.52).
  • Q2 FY27 results (consolidated, filed 14 Nov 2026): revenue ₹341 crore (+76.3% year on year), net profit ₹29 crore; the price moved +4.5% on the first session after.
  • Promoters held 74.45% at 30 Sept 2026, unchanged on the previous filing.
  • Q3 FY27 results are expected between 10 Feb 2027 and 13 Feb 2027, going by past filing dates — an estimate, not an announcement.

About

Macro sectorHealthcare
Basic industryPharmaceuticals
ISININE191A01027
SeriesEQ
Listed2 Nov 2020
NSE market cap · 17 Nov 2026₹5,574 Cr
Free-float market cap (NSE)₹1,681 Cr
Shares outstanding (NSE)5.99Cr
History from3 Nov 2020
Sessions1,499
Turnover rank#975

Prices are adjusted for splits and bonuses. Delivery figures come from NSE’s daily reports and are unavailable for older sessions. Sourced from the eod2 dataset, last updated 20 Nov 2026.